Erkurt, Mehmet AliKuku, LrfanKaya, EminOzgen, UnsalBerber, IlhamiKoroglu, MustafaOzgul, Mustafa2024-08-042024-08-0420131473-0502https://doi.org/10.1016/j.transci.2013.04.012https://hdl.handle.net/11616/96089Therapeutic plasma-exchange (TPE) is used as primary and adjunctive therapy in treatment of several hematologic diseases. We retrospectively evaluated the results of TPE in hematologic diseases during 2008-2012. A total of 301 TPE procedures were performed in 44 patients (19 male and 25 female, with mean age of 50.6 +/- 15 years). Fifteen of 44 patients had thrombotic thrombocytopenic purpura (TTP), 14 patients had HELLP syndrome (Hemolysis Elevated Liver enzymes, Low Platelet count), 10 patients had multiple myeloma-hyperviscosity and the rest five patients had snake bite. Fresh frozen plasma (FFP) was used as replacement fluid. Complete response (CR) was achieved on 13 patients (87%) in primarily TTP. CR was achieved in all other three diseases. Total complications were detected in 8.1% of the TPE procedures. Adverse events (AEs), were seen in 5.4% of all procedures. None of the patients died from any complication. AE occurred in 4% (Grade-I), 1% (Grade-II), and 0.3% (Grade-III) of the procedures. The most common AE were nausea/vomiting, hypotension, pruritus and abdominal pain. TPE is effectively and safely carried out in our center in hematologic diseases. (C) 2013 Elsevier Ltd. All rights reserved.eninfo:eu-repo/semantics/closedAccessTherapeutic plasma exchangePlasmapheresisAdverse eventsArticle4833353392361932310.1016/j.transci.2013.04.0122-s2.0-84878836269Q3WOS:000321403400013Q4